Clinical Trials Directory

Trials / Unknown

UnknownNCT02902276

Link Between Plasma Citrulline and Lipopolysaccharide Concentrations in the Critically Ill

Status
Unknown
Phase
Study type
Observational
Enrollment
120 (estimated)
Sponsor
Centre Hospitalier Universitaire de Besancon · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

In critically ill patients, the small bowel permeability is increased, leading to bacterial translocation, and systemic inflammatory response syndrome. Plasma citrulline is a validated biomarker of functional enterocyte mass. Lipopolysaccharide (LPS) is a part of Gram negative bacteria, and plasma LPS concentration is a biomarker of bacterial translocation. The link between plasma citrulline and LPS in the critically ill is unknown. Investigators hypothesize that patients presenting with low plasma citrulline concentration, with presumed altered small bowel function, would have an increased phenomenon of bacterial translocation, and increased plasma LPS concentration. Investigators aimed to evaluate the link between plasma citrulline and LPS concentrations in critically ill patients at the time of ICU admission.

Conditions

Interventions

TypeNameDescription
OTHERadditional blood sampleTwo blood samples will be taken at ICU admission

Timeline

Start date
2016-07-01
Primary completion
2017-02-01
Completion
2017-02-01
First posted
2016-09-15
Last updated
2016-09-15

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02902276. Inclusion in this directory is not an endorsement.

Link Between Plasma Citrulline and Lipopolysaccharide Concentrations in the Critically Ill (NCT02902276) · Clinical Trials Directory